Fig. 5.

Macrophage depletion mitigates IL-4 benefits on ALI resolution. A: BAL macrophage and BAL neutrophil number at day 5 after intratracheal LPS and IL-4 in mice receiving either liposomal clodronate (macrophage depleted) or PBS liposomes (control) (n = 4–5, *P < 0.05 by t-test). B: BAL protein and BAL albumin at day 5 quantified in both groups following IL-4 therapy (n = 4–5, **P < 0.01 by t-test). C: percent depletion of alveolar (AM; F4/80⁺CD11c⁺) and interstitial (IM; F4/80⁺CD11b⁺) macrophage subpopulations, as well as the percentage and MFI of MMR expression among these cells (n = 4–5, *P < 0.05, **P < 0.01, and ***P < 0.001 by t-test).